Sexual health

PT-141

Bremelanotide. Melanocortin receptor agonist FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Off-label use in men and post-menopausal women is common; mechanism is central rather than vascular. Subcutaneous; ~6h onset.

Medically reviewed by Marko Maal · May 6, 2026

Reviewed by Marko Maal, MSc Pharmacy · University of Tartu · Pharmaceutical sciences — drug sourcing, formulation, regulatory review · Reviewed May 6, 2026

Reviewed for clinical and pharmacological accuracy by Marko Maal, MSc Pharmacy.

Common doses

IndicationRouteDoseDurationEvidence
HSDD (premenopausal women, on-label)SC injection (Vyleesi)1.75 mg as needed, 45 min before sex; max 8/monthPRNTier 1
Off-label sexual dysfunction (research-chemical PT-141)SC injection or intranasal0.5–2 mg SC or 5–20 mg intranasal as neededPRNTier 3

What the community reports — PT-141

distilled from 8 Reddit posts

Users report nausea as primary concern and avoid daily use due to anhedonia risk.

Reported dose
1-2 mg
Route
intranasal spray,injectable
Frequency
not daily
Side effects
nausea, insomnia
Often stacked with
Viagra, Cialis, Melanotan II

Ask about PT-141

Get an answer from our reviewed articles and community reports, with links to the sources. Not medical advice.

Overview

PT-141 — generic name bremelanotide, brand name Vyleesi — is the only FDA-approved peptide for sexual dysfunction. It was approved in June 2019 specifically for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, after pivotal trials (RECONNECT) enrolling 1,247 women demonstrated statistically significant improvement in sexual desire and reduction of distress.

The molecule's distinguishing feature is its mechanism. Conventional sexual-dysfunction drugs — sildenafil, tadalafil, vardenafil — act peripherally on smooth muscle and blood vessels. They enable arousal in the presence of desire but do nothing for desire itself. PT-141 acts centrally, in the brain, on the melanocortin receptor system. It addresses the desire and arousal pathways themselves rather than the vascular response.

That central mechanism produces a different effect profile and a different side-effect profile from PDE5 inhibitors. The trade-off pattern matters when patients consider it.

How it works

Evidence tier: 2 — mechanism documented in published pharmacology literature.

PT-141 is a non-selective melanocortin receptor agonist with primary activity at MC3R and MC4R receptors in the central nervous system. Activation of these receptors in specific hypothalamic and limbic regions modulates dopaminergic and oxytocin pathways involved in sexual desire and arousal — the same pathways that natural arousal recruits.

The downstream effect is an enhancement of subjective sexual desire and physiological arousal that is fundamentally upstream of the vascular response to arousal. This is why PT-141 can be effective in men and women with erectile dysfunction or arousal disorders that are partly or wholly central in origin, where PDE5 inhibitors fail.

The trade-off: melanocortin receptors are not exclusive to sexual pathways. MC1R activity contributes to skin pigmentation; chronic high-dose use produces hyperpigmentation in some patients. Melanocortin receptors in the brainstem and cardiovascular regions contribute to the side-effect profile — particularly the transient blood pressure elevation seen in many patients.

Evidence, on-label vs off-label, and side effects

Evidence tier: 2 — references summarized in the body; see Trial readouts section below for primary-source detail.

On-label evidence is strong:

  • RECONNECT trials (2016–2017): n=1,247 premenopausal women with HSDD, randomized 1:1 to bremelanotide vs placebo. Statistically significant improvement in Female Sexual Function Index desire score and reduction in associated distress. Tier 1.
  • Long-term open-label extension showed sustained effect with continued use.

Off-label use is common — for men with erectile dysfunction unresponsive to PDE5 inhibitors, for postmenopausal women, for couples seeking a desire enhancer rather than just an arousal enabler. Off-label efficacy data is limited; published trials in these populations are sparse.

Side effects:

  • Nausea is the most common — affects up to 40% of patients on first dose, decreases substantially with subsequent use.
  • Flushing.
  • Injection-site reactions.
  • Headache.
  • Transient blood pressure elevation — a real cardiovascular consideration. Contraindicated in uncontrolled hypertension or established cardiovascular disease.
  • Hyperpigmentation with chronic high-dose use.
  • Theoretical interaction with monoaminergic drugs and stimulants.

Avoid in pregnancy, lactation, recent or untreated cardiovascular disease, severe hypertension. Patients with history of melanoma or atypical nevi should be evaluated before use given MC1R activity.

Practical considerations

Evidence tier: 5 — community-evolved dose-range guidance; not RCT-derived.
  • On-label dosing. Vyleesi: 1.75 mg subcutaneously, as needed, 45 minutes before anticipated sexual activity. Maximum 8 doses per month.
  • Off-label dosing. Research-chemical PT-141 is dosed by community protocols at 0.5–2 mg subcutaneously or 5–20 mg intranasally. Intranasal bioavailability is significantly lower (~20%) than subcutaneous (~100%), requiring proportionally higher doses.
  • Onset and duration. Effect begins 30–60 minutes post-dose; subjective effect typically lasts 4–8 hours.
  • Cost. Branded Vyleesi is expensive — typically $50–100 per autoinjector, often not insurance-covered. Compounded or research-chemical versions cost less but carry the usual quality-verification burden.
  • First-dose strategy. Given the high nausea rate on first dose, many clinicians recommend starting with a low test dose (e.g. 0.5 mg) at home, not before a sexual encounter, to characterize the individual side-effect response.

Where to go from here

For the broader Sexual Health pillar including melanotan II and other less-evidenced peptides, see the goal-based hub. For the pharmacology of melanocortin receptors and other MSH-derived peptides like KPV, see the cognitive and immune-gut pillars.

Related on Peptide Story

References

Limitations · Who should NOT use this

Common side effects: nausea (up to 40% on first dose, decreases with use), flushing, injection-site reactions, headache. Important: PT-141 raises blood pressure transiently in many patients — contraindicated in uncontrolled hypertension or cardiovascular disease. Hyperpigmentation reported with chronic high-dose use due to MC1R cross-activity. Avoid in pregnancy, lactation, recent or untreated cardiovascular disease, or in combination with stimulants.

Regulatory notes

FDA-approved as Vyleesi in June 2019 for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Not approved for men, postmenopausal women, or for erectile dysfunction. Off-label use is common; off-label efficacy and safety data is limited.

External · Independent testing

Verify what's actually in your PT-141 vial

Gray-market peptide vials vary widely on identity, purity, and labeled concentration. Finnrick is an independent testing platform that ships consumer-submitted samples to commercial labs and publishes every result in a free public database. Vendors cannot pay for placement or to suppress a result. We don't operate Finnrick — we link to it because post-purchase verification is the right complement to pre-purchase clinical evidence.

Finnrick is independent; we receive no compensation for this link. US-resident free testing as of May 2026.

Where to buy

PT-141 — cheapest verified vendors

VendorProductSizePricePrice / mgTrust
Peptide PartnersPT-141 100mg100 mg vial$84.00$0.84/mg40Buy
Reta PeptidePT-141 100mg100 mg vial$85.00$0.85/mg40Buy
Atomik LabzPT-141 100mg100 mg vial$333.00$3.33/mg40Price n/a
Verified PeptidesPT-141 10mg10 mg vial$34.99$3.50/mg40Price n/a
Peptide CraftersPT-141 10mg10 mg vial$35.00$3.50/mg40Price n/a

Prices refreshed 8 hours ago. Links may be affiliate links; how are trust scores calculated?

See all 52 vendors for PT-141 →

Sources

  1. Clayton AH, et al. RECONNECT: Women's Health 2016;12(3):325-337.
  2. Pfaus J, et al. Bremelanotide for sexual dysfunction: Curr Sex Health Rep 2007;4(1):28-33.
  3. FDA Vyleesi prescribing information.

More on PT-141

What Reddit users report — PT-141

Best-rated real posts mentioning PT-141, summarized with a short quote in the poster’s own words. Of these: 2 mixed. Anecdotal community signal — not evidence, not medical advice, and not endorsement.

  • ~ Mixedr/Peptides

    Female user ordered intranasal PT-141 spray seeking libido improvement while on testosterone and progesterone therapy. No outcome reported yet.

    — u/Koriani · read on Reddit ↗
  • ~ Mixedr/Peptides

    User tried 1mg PT-141, experienced some benefits with mild nausea. Seeking safe dosing frequency to avoid anhedonia.

    “noticed some of the benefits as well as some slight nausea but nothing crippling or overwhelming”
    — u/FroyoZestyclose8180 · read on Reddit ↗

Posts are pulled from public Reddit threads and summarized for context. Individual experiences vary widely and don’t predict your own results. Always consult a qualified clinician.

Community signal — PT-141

Recent posts and videos mentioning PT-141 from the cron-ingested Reddit + X pipelines and the curated /experts directory. Not endorsement — directional context only.

Community experiences

2 approved · moderated

First-hand accounts from readers who've used PT-141. These are personal anecdotes, not clinical evidence or medical advice — every post is reviewed before it appears.

  • Leo A··3 min read
    Member

    PT-141 experience — Leo A

    I’m 46, married, live in Southern California, and run my own business. I’d been on TRT through my doctor for a few years already. My bloodwork was generally fine and I usually didn’t have much trouble physically getting an erection, but my interest in sex had gotten really inconsistent.

    At the time I honestly didn’t make much of a distinction between libido, erections, hormones, stress, all of that. If something felt off sexually, I basically assumed it was all part of the same problem.

    That’s what got me interested in PT-141.

    I’d read a bunch of posts about it and some people made it sound almost absurdly effective. Like you take it and suddenly the switch flips. I think part of me wanted to use it as a test. If I responded strongly, I figured that would mean there was some biological or hormonal explanation for what I was experiencing.

    That turned out to be way too simplistic.

    I tried prescribed bremelanotide a few times. I wasn’t taking it regularly, and at least in the beginning I didn’t mix it with other sexual-health meds because I wanted to know what it was actually doing on its own.

    The first time, there was definitely an effect. No question. I also got pretty noticeable nausea, so it wasn’t exactly some magical experience.

    The second time was probably the strongest in terms of actually feeling more interested in sex. The weird part was that it didn’t feel the way I expected. I thought it would feel like normal spontaneous desire, just stronger. Instead, I was very aware that something had changed, but it felt a little more mechanical or pushed than I expected.

    Then the third time, the effect was weaker even though I hadn’t really changed anything major.

    That was probably the point where I stopped thinking I was going to get some clean answer out of it.

    Before that, I had a bad habit of treating every sexual experience like data about my testosterone. Good night? Hormones must be fine. Bad night? Maybe my TRT is off. Looking back, that was pretty ridiculous because there were so many other variables involved.

    Sleep. Stress. Work. My relationship. Whether I actually felt mentally present. Whether I was attracted and interested but just exhausted. Whether I wanted sex or just wanted to know that I could perform.

    Those are not the same thing.

    That was probably the most useful thing PT-141 showed me. Not whether it “worked,” because yes, it did something. The useful part was realizing that getting a noticeable sexual response didn’t automatically explain why my libido had been inconsistent in the first place.

    If I could do it over again, I’d spend more time figuring out what problem I was actually trying to solve before reaching for something to solve it.

    Was the problem desire? Erections? Confidence? Stress? Feeling disconnected from my wife? Just being tired all the time?

    I also would have talked to my wife about it earlier instead of treating it like some private troubleshooting project.

    I think that’s the part a lot of PT-141 discussions miss. People ask, “Did it work?”

    For me, that question is too broad.

    What changed?

    Did you want sex more? Did you get more physically aroused? Did erections improve? Did you feel more confident? Did you actually feel closer to your partner? And what didn’t change?

    PT-141 gave me a pretty obvious response, but it also made me realize that libido and erection quality are two different things, and neither one tells you the whole story by itself.

  • Robert M··1 min read
    Member

    PT-141 experience — Robert M

    I’m 56, live in Phoenix, and I’ve been on TRT for about six years. I started after my testosterone came back around 280 ng/dL. TRT improved my energy, recovery, and libido for several years, but over the last year or so, my desire started fading.

    It wasn’t really erectile dysfunction. I could still get an erection and have sex, but the arousal and wanting just felt muted. Cialis 5 mg daily improved erection quality, but it didn’t fix that part.

    After hearing about PT-141 on a podcast, I asked my TRT provider about it. I kept my TRT and Cialis the same and added PT-141 occasionally, usually no more than twice a week.

    My first dose was 1.5 mg. About 90 minutes later I had pretty strong nausea and some facial flushing. The actual arousal effect took much longer than I expected, starting around five hours later and peaking closer to seven hours.

    After a few tries, I found that taking 1.5 mg with food worked best for me and made the nausea much easier to handle. I tried 2 mg once, but the extra nausea wasn’t worth it.

    The biggest difference for me was that Cialis helped with erection quality, while PT-141 helped more with desire and arousal. They weren’t competing treatments; they were doing different things.

    PT-141 wasn’t magic or spontaneous. It required planning, and the side effects were real at first. If I started again, I’d probably begin closer to 1 mg and treat the first vial as a trial.

    My main takeaway is that not every sexual-health problem is an erection problem. Sometimes performance is still there, but the desire and arousal response have gone quiet. For me, PT-141 helped with the part Cialis didn’t.

Community Notes

0 approved · moderated

Structured notes from readers — context, citations, corrections, and first-hand experience. Every note is moderated before it appears. Notes do not replace medical review; they supplement it.

No approved notes yet.

Know something that should be on this page? A citation, clarification, or dispute? Sign in and submit the first note.

Submission interface coming in Phase 2. For now, notes are authored in Studio. See the Community Guidelines for moderation criteria.

← All peptides